Needham & Company LLC reissued their hold rating on shares of Shattuck Labs (NASDAQ:STTK - Free Report) in a report published on Thursday morning,Benzinga reports.
Several other equities research analysts also recently commented on the stock. Leerink Partnrs upgraded shares of Shattuck Labs to a "strong-buy" rating in a research note on Monday, March 17th. Leerink Partners initiated coverage on shares of Shattuck Labs in a research note on Monday, March 17th. They set an "outperform" rating and a $4.00 price objective on the stock. Finally, HC Wainwright reiterated a "neutral" rating on shares of Shattuck Labs in a research note on Thursday. Four analysts have rated the stock with a hold rating, one has assigned a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $7.50.
View Our Latest Report on STTK
Shattuck Labs Price Performance
Shares of NASDAQ STTK traded down $0.10 during trading hours on Thursday, reaching $0.95. The stock had a trading volume of 97,503 shares, compared to its average volume of 377,186. The company has a market cap of $45.36 million, a price-to-earnings ratio of -0.62 and a beta of 1.66. Shattuck Labs has a twelve month low of $0.94 and a twelve month high of $11.76. The business's fifty day moving average is $1.24 and its two-hundred day moving average is $1.46.
Shattuck Labs (NASDAQ:STTK - Get Free Report) last issued its earnings results on Thursday, March 27th. The company reported ($0.37) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.01. Shattuck Labs had a negative net margin of 1,156.46% and a negative return on equity of 61.92%. Sell-side analysts forecast that Shattuck Labs will post -1.48 earnings per share for the current fiscal year.
Institutional Trading of Shattuck Labs
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in STTK. Zacks Investment Management bought a new position in Shattuck Labs in the fourth quarter valued at approximately $25,000. Virtu Financial LLC acquired a new stake in shares of Shattuck Labs during the fourth quarter worth $30,000. Atom Investors LP bought a new stake in Shattuck Labs in the third quarter valued at about $35,000. Readystate Asset Management LP acquired a new position in Shattuck Labs in the third quarter valued at about $39,000. Finally, Schonfeld Strategic Advisors LLC bought a new position in Shattuck Labs during the fourth quarter worth about $45,000. 58.74% of the stock is currently owned by institutional investors and hedge funds.
Shattuck Labs Company Profile
(
Get Free Report)
Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.
See Also
Before you consider Shattuck Labs, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Shattuck Labs wasn't on the list.
While Shattuck Labs currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
